2 assets in Diffuse Scleroderma

Therapeutic assets addressing Diffuse Scleroderma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Rapcabtagene Autoleucel Diffuse Scleroderma	Novartis Pharmaceuticals	P2	CCC (53)
Rituximab Diffuse Scleroderma	Novartis Pharmaceuticals	P2	CCC (53)